Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Endothelial Dysfunction as a Risk Factor in HIV Study
- Conditions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 75
- Registration Number
- NCT00039663
- Locations
- 🇺🇸
National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States
Prevention of Kidney Transplant Rejection
- Conditions
- Locations
- 🇺🇸
Ilene Blechman-Krom, Rockville, Maryland, United States
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2006-03-14
- Target Recruit Count
- 56
- Registration Number
- NCT00017758
- Locations
- 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Washington Univ School of Medicine, St Louis, Missouri, United States
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 630
- Registration Number
- NCT00006412
- Locations
- 🇺🇸
Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States
🇺🇸Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 56
- Registration Number
- NCT00000941
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸Stanford Univ Med Ctr, Stanford, California, United States
Effect of Pravastatin on Endothelial Dysfunction Following a Single High Fat Meal
- Conditions
- First Posted Date
- 2000-04-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00005117
- Locations
- 🇺🇸
4200 E. 9th Avenue, Box B133, Denver, Colorado, United States
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Arterial Disease Multifactorial Intervention Trial (ADMIT)
- Conditions
Harvard Atherosclerosis Reversibility Project (HARP)
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.